Omnihealth Practice

DIABETES & ENDOCRINOLOGY

More than glycated hemoglobin: Dapagliflozin preserves cardiorenal functions in patients with type 2 diabetes mellitus

21 Sep 2021

Breaking the vicious cycle of cardiac, renal and metabolic risks in patients at risk of chronic kidney disease

13 Jul 2021

What not to ignore when diabetes interacts with acute and chronic kidney diseases: A local case sharing

30 Dec 2020

Managing the early-onset type 2 diabetes mellitus: Target the major hurdles

29 Jun 2020

Managing the early-onset type 2 diabetes mellitus: Target the major hurdles

People with young-onset diabetes have a worse metabolic risk profile compared to those with late-onset disease. This group has higher risks for cardiovascular and kidney complications at any given age, driven by the longer disease duration.1 In Hong Kong, while the mortality rate decrease in people

29 Jun 2020

Dr. Luk, On-Yan Andrea

Associate Professor,
Department of Medicine & Therapeutics,
The Chinese University of Hong Kong

ENDO 2021

March 20-23, 2021 |

Virtual

New insights into dapagliflozin: The revolutionary road in diabetic kidney complications

NEPHROLOGY DIABETES & ENDOCRINOLOGY

07 Jan 2022

Professor Mark Cooper

Department of Diabetes,
Central Clinical School,
Monash University,
Melbourne, Australia

What not to ignore when diabetes interacts with acute and chronic kidney diseases: A local case sharing

While they may not necessarily have a causal relationship, both chronic kidney disease (CKD) and diabetes mellitus (DM) have become increasingly more prevalent worldwide.1 As these conditions could be risk factors for developing acute kidney injury (AKI),2 CKD and DM must be carefully managed to pre

30 Dec 2020

Dr. Cheung, Siu-Fai

Specialist in Nephrology

Comparing the newly FDA-approved tirzepatide with insulin glargine in T2DM patients at high CV risk: The SURPASS-4 trial

Tirzepatide was approved by the U.S. Food and Drug Administration (FDA) on May 13, 2022 as the first and only dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist for type 2 diabetes mellitus (T2DM), given its potent glucose-lowering effects.1

25 Jul 2022

Dasiglucagon shown as a promising therapeutic for severe hypoglycemia in a recent phase 3 trial

Published recently in Diabetes Care, a phase 3 study demonstrated the rapid hypoglycemia reversing capability of dasiglucagon among adult patients with type 1 diabetes mellitus (T1DM) who were experiencing severe insulin-induced hypoglycemia.1 Together with the results from similar studies targeting

29 Jun 2021

DIABETES & ENDOCRINOLOGY GASTROENTEROLOGY & HEPATOLOGY

Caution: The risk of severe hypoglycemia is elevated in diabetic adults with NAFLD

30 May 2022